Liu Menglu, Li Jiawen, Yan Kailun, Zhang Kexin, Zhu Pei, Tang Xiaofang, Yuan Deshan, Yang Yuejin, Gao Runlin, Yuan Jinqing, Zhao Xueyan
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People's Republic of China.
Diabetol Metab Syndr. 2025 May 13;17(1):151. doi: 10.1186/s13098-025-01716-6.
The risk of bleeding associated with antiplatelet therapy in patients with coronary artery disease (CAD) has received a lot of attention. The aim of this study was to investigate the relationship between ABO blood system and low on-treatment platelet reactivity (LTPR) in patients with CAD and type 2 diabetes mellitus (T2DM).
This study examined 10,724 consecutive patients who received percutaneous coronary intervention in China between January and December in 2013 and applied logistic regression to assess the association between ABO blood types and LTPR. These patients who were diagnosed with T2DM, had thromboelastogram (TEG) results and were administered clopidogrel were ultimately enrolled. LTPR is defined by a platelet maximum amplitude of < 31 mm on TEG, induced by adenosine diphosphate.
Among 3,039 patients (mean age, 59.35 ± 9.89; male, 74.60%), 1,089 (35.83%) presented with LTPR. Multivariate logistic regression revealed that blood type O was independently related to higher odds of LTPR (OR : 1.298, 95% CI 1.099-1.534) and that blood type A was independently related to lower odds of LTPR (OR : 0.804, 95% CI 0.674-0.958). For further analysis, multivariate logistic regression revealed that, compared to blood type A, type O was independently related to higher odds of LTPR (OR : 1.409, 95% CI 1.147-1.729).
This study reported that in patients with CAD and T2DM, blood type O was independently associated with higher odds of LTPR, indicating a greater likelihood of bleeding, while blood type A was independently related to lower odds of LTPR, suggesting a reduced likelihood of bleeding.
冠状动脉疾病（CAD）患者抗血小板治疗相关的出血风险受到了广泛关注。本研究旨在探讨CAD合并2型糖尿病（T2DM）患者ABO血型系统与治疗中低血小板反应性（LTPR）之间的关系。
本研究对2013年1月至12月在中国接受经皮冠状动脉介入治疗的10724例连续患者进行了检查，并应用逻辑回归分析评估ABO血型与LTPR之间的关联。最终纳入了这些被诊断为T2DM、有血栓弹力图（TEG）结果且接受氯吡格雷治疗的患者。LTPR定义为TEG上由二磷酸腺苷诱导的血小板最大振幅<31mm。
在3039例患者（平均年龄59.35±9.89岁；男性占74.60%）中，1089例（35.83%）出现LTPR。多因素逻辑回归显示，O型血与LTPR的较高几率独立相关（OR：1.298，95%CI 1.099-1.534），而A型血与LTPR的较低几率独立相关（OR：0.804，95%CI 0.674-0.958）。为进一步分析，多因素逻辑回归显示，与A型血相比，O型血与LTPR的较高几率独立相关（OR：1.409，95%CI 1.147-1.729）。
本研究报告称，在CAD合并T2DM患者中，O型血与LTPR的较高几率独立相关，表明出血可能性更大，而A型血与LTPR的较低几率独立相关，提示出血可能性降低。
